Cat. No. 3822
Chemical Name: 6-[2-(5,6,7,8-Tetrahydro-5,5,8,8-te
Biological ActivitySelective RARγ antagonist. Blocks the growth inhibitory ability of RARγ-selective agonists in squamous cell carcinoma (SCC)-25 cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Dawson et al (2001) Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res. 61 4723. PMID: 11406543.
Holmes et al (2000) Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. J.Cell.Physiol. 185 61. PMID: 10942519.
Le et al (2000) Modulation of retinoic acid receptor function alters the growth inhibitor response of oral SCC cells to retinoids. Oncogene 19 1457. PMID: 10723137.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for MM 11253 include:
Garnaas et al (2012) Rargb regulates organ laterality in a zebrafish model of right atrial isomerism. Dev Biol 372 178. PMID: 22982668.
Do you know of a great paper that uses MM 11253 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: MM 11253, supplier, MM11253, retinoids, retinoic, acid, receptors, antagonists, rarg, rargamma, rarγ, Tocris Bioscience, Retinoic Acid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Synthetic retinoid; induces differentiation of stem cellsSI-2 hydrochloride
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.